Actively Recruiting

All Genders
NCT04367883

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Led by Consorci Sanitari de Terrassa · Updated on 2026-03-25

3000

Participants Needed

1

Research Sites

416 weeks

Total Duration

On this page

Sponsors

C

Consorci Sanitari de Terrassa

Lead Sponsor

F

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Collaborating Sponsor

AI-Summary

What this Trial Is About

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

CONDITIONS

Official Title

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Hospital admissions at the Hospital of Terrassa from March 1, 2020 for any cause.
Not Eligible

You will not qualify if you...

  • Patients from outside the reference area of the Terrassa Health Consortium would be excluded for comparison of percentage of Influenza vaccination, ACEI and ARB vs general population.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hospital de Terrassa

Terrassa, Barcelona, Spain, 08227

Actively Recruiting

Loading map...

Research Team

A

Anna Puigdellívol-Sánchez, Ph.D.

CONTACT

M

Mar Muñoz

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here